Evaluation of the safety and immunogenicity of pneumococcal seven-valent conjugate vaccine (Prevenar®) administered in previously unvaccinated Spanish children aged 24 to 36 months
2004; Elsevier BV; Volume: 23; Issue: 16 Linguagem: Inglês
10.1016/j.vaccine.2004.10.024
ISSN1873-2518
AutoresJ. de Arístegui Fernández, Begoña Cos Arregui, Ana Zurimendi Carril, M Victoria Alday Esteban, Javier Alzua Ruiz, Emma De la Fuente Jausoro, Inmaculada Maturana San Pedro, Malkoa Michelena, Carlos Mourelo Carballo, Maria Isabel Quintanilla Sánchez, Inmaculada Abad Therón, C Cimino, Mark A. Fletcher, Ana Pérez Domínguez,
Tópico(s)Respiratory viral infections research
ResumoThis study evaluate the safety and immunogenicity of pneumococcal seven-valent conjugate vaccine (Prevenar®) in 115 children, aged 2–3 years (24–36 months), who have not been previously vaccinated with Prevenar®. Safety: As for local reactions, 40% of children reported erythema, 32.2% induration and 39.1% tenderness at the injection site. Regarding systemic reactions, fever ≥38C was recorded in 7% of patients. Other commonly reported events were decreased appetite (24.3%), restlessness (20%), and fussiness (18.3%). After vaccination, more than 98% of the subjects achieved antibody levels of ≥0.15 μg/mL for all seven serotypes and more than 95% achieved antibody levels ≥0.50 μg/mL for all serotypes. Pneumococcal seven-valent conjugate vaccine (Prevenar®) was safe, well tolerated and highly immunogenic when administered in previously unvaccinated children aged 24–36 months.
Referência(s)